Business Description
Oxford BioMedica PLC
ISIN : GB00BDFBVT43
Total Employee Number:
986Description
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.65 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 1.62 | |||||
Debt-to-EBITDA | 61.41 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.86 | |||||
Beneish M-Score | -2.76 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.7 | |||||
3-Year EPS without NRI Growth Rate | 17.7 | |||||
3-Year FCF Growth Rate | 50.1 | |||||
3-Year Book Growth Rate | -29.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 26.25 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.76 | |||||
9-Day RSI | 42.39 | |||||
14-Day RSI | 43.21 | |||||
3-1 Month Momentum % | 19.13 | |||||
6-1 Month Momentum % | 2.76 | |||||
12-1 Month Momentum % | 97.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.2 | |||||
Quick Ratio | 2 | |||||
Cash Ratio | 1.15 | |||||
Days Inventory | 55.05 | |||||
Days Sales Outstanding | 52.2 | |||||
Days Payable | 40.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.8 | |||||
Shareholder Yield % | -9.83 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 39.1 | |||||
Operating Margin % | -19.53 | |||||
Net Margin % | -17.86 | |||||
EBITDA Margin % | 1.43 | |||||
FCF Margin % | -2.49 | |||||
OCF Margin % | 0.33 | |||||
ROE % | -49.9 | |||||
ROA % | -11.68 | |||||
ROIC % | -18.14 | |||||
3-Year ROIIC % | -21.01 | |||||
ROC (Joel Greenblatt) % | -23.01 | |||||
ROCE % | -9.32 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.21 | |||||
PB Ratio | 8.37 | |||||
Price-to-Tangible-Book | 11.49 | |||||
Price-to-Operating-Cash-Flow | 904.29 | |||||
EV-to-EBIT | -46.89 | |||||
EV-to-Forward-EBIT | -72.01 | |||||
EV-to-EBITDA | 338.89 | |||||
EV-to-Forward-EBITDA | 36.31 | |||||
EV-to-Revenue | 4.84 | |||||
EV-to-Forward-Revenue | 3.6 | |||||
EV-to-FCF | -192.15 | |||||
Price-to-GF-Value | 1.11 | |||||
Price-to-Median-PS-Value | 0.64 | |||||
Earnings Yield (Greenblatt) % | -2.13 | |||||
FCF Yield % | -0.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:OXBDF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oxford BioMedica PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 227.222 | ||
| EPS (TTM) ($) | -0.365 | ||
| Beta | 1.5112 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.83 | ||
| Volatility % | 78.96 | ||
| 14-Day RSI | 43.21 | ||
| 14-Day ATR ($) | 0.06696 | ||
| 20-Day SMA ($) | 7.95104 | ||
| 12-1 Month Momentum % | 97.99 | ||
| 52-Week Range ($) | 4.23 - 12.61 | ||
| Shares Outstanding (Mil) | 121.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oxford BioMedica PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oxford BioMedica PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-23 08:00 | In 84 days | ||
| Second quarter earnings results for 2026 | 2026-09-23 | In 83 days | ||
| General meeting for 2026 | 2026-05-07 14:00 | 8.05 (+0.00%) | ||
| Annual report for 2025 | 2026-03-30 | 8.17 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 13:00 | 8.17 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 8.17 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-23 08:00 | 8.26 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-23 | 8.26 (+0.00%) | ||
| General meeting for 2025 | 2025-06-11 15:00 | 4.66 (+0.00%) | ||
| Annual report for 2024 | 2025-04-28 | 3.95 (+0.00%) |
Show
Entries
Oxford BioMedica PLC Frequently Asked Questions
What is Oxford BioMedica PLC(OXBDF)'s stock price today?
The current price of OXBDF is $7.93. The 52 week high of OXBDF is $12.61 and 52 week low is $4.23.
When is next earnings date of Oxford BioMedica PLC(OXBDF)?
The next earnings date of Oxford BioMedica PLC(OXBDF) is 2026-09-23 Est..
Does Oxford BioMedica PLC(OXBDF) pay dividends? If so, how much?
Oxford BioMedica PLC(OXBDF) does not pay dividend.
Guru Commentaries on OTCPK:OXBDF
No articles.
Press Release
Articles on Oxford BioMedica PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers